

# A simple method for preparation of immuno-magnetic liposomes

Maryam M. Elmi, Mohammad N. Sarbolouki \*

*Institute of Biochemistry and Biophysics, Tehran University, PO Box 13145–1384, Tehran, Iran*

Received 12 April 2000; received in revised form 25 October 2000; accepted 3 November 2000

---

## Abstract

A simple and readily manoeuvrable method for preparing immuno-magnetic liposomes that indigenously contain binding sites for attaching other molecules like antibodies on their exterior surface is described. In this method magnetic unilamellar vesicles are prepared from a mixture of phosphatidylcholine, cholesterol, small amounts of a linear chain aldehyde and colloidal particles of magnetic iron oxide, using a reverse phase evaporation technique. The aldehyde (dedecanal) molecules align themselves among the lipid molecules in the bilayer with their aldehyde groups exposed to the aqueous phase, allowing straight attachment of antibody molecules (human-antimouse IgG-FITC in this case) in one single step. The success of this approach is confirmed by fluorescence microscopy as well as binding of the resulting immuno-magnetic liposomes to their corresponding target cells. © 2001 Elsevier Science B.V. All rights reserved.

*Keywords:* Liposomes; Immuno-liposomes; Magnetic; Antibody; Attachment; Aldehyde; Immuno-magnetic

---

## 1. Introduction

Ever since their discovery, liposomes (lipid vesicles) have been a subject of great interest in a wide variety of applications, namely as simplified biomembrane models or as potential biocompatible carriers of genetic and pharmaceutical agents (Bangham and Horn, 1964; Gregoriadis and Allison, 1980; Knight, 1981; Gregoriadis and Florence, 1992; Ostro, 1987; Peeters et al., 1987; Pidgeon and Hunt, 1987; Lopez-Berestein and Fidler, 1989; Gray and Morgan, 1991; Jones and

Chappman, 1995). Despite the extensive efforts and achievements, there still are many obstacles to their in-vivo use as drug carriers in the body, e.g. their recognition and capture by the defence system and their accumulation in the liver and spleen (Gregoriadis and Ryman, 1972). Many approaches have been improvised to avoid such problems and to increase their lifetime in blood (Patel and Baldeschwieller, 1983; Proffit, 1986; Allen and Chonn, 1987; Gabizon and Papahadjopoulos, 1988; Allen and Hasan, 1989; Klivanov et al., 1991; Gabizon, 1992; Woodle and Lasic, 1992), e.g. the use of immunoliposomes (Huang et al., 1980; Stonsons and Mallett, 1981; Schwendener et al., 1990), pH sensitive (Yatvin and

---

\* Corresponding author.

E-mail address: sarbol@ibb.ut.ac.ir (M.N. Sarbolouki).

Krutz, 1980; Connor and Huang, 1986; Holmberg and Reuer, 1994), and thermosensitive liposomes (Yatvin and Weinstein, 1990; Viroonchatapan and Sato, 1996). Another alternative has been the introduction of magneto-sensitive liposomes in order to help localize the drug loaded particles at therapeutic site of interest, (Margolis and Namit, 1983; Kato and Kiwada, 1986; De Cuypur and Joniau, 1988; Scheffold and Milteni, 1995; Viroonchatapan and Sato, 1996).

Several techniques have been developed and applied for attachment of antibodies to the exterior surface of liposomes, (Huang and Kennel, 1979; Magee and Miller, 1979; Sollivan and Huang, 1986; Wessing and Lasch, 1986; Wang and Huang, 1989; Allen, 1990; Furukawa and Sahasrabudde, 1990). For example, glutaraldehyde, carbodiimide, and *N*,succinimidyl-3-(2-pyridyldithio) propionate has been used as a bridge for the coupling of antibodies onto liposomes, (Torchilin and Khaw, 1979; Allen et al., 1995; Hansen et al., 1995; Aslam and Dent, 1998). However, glutaraldehyde is highly reactive and may inadvertently interact with other proteins, thereby affecting their performance. Besides, the number of functional groups that appear on liposome surfaces cannot be known quantitatively. The second compound suffers from the disadvantage that it only attaches to phosphatidylethanolamine thus it is of limited use and cannot be used for liposomes lacking this component. Therefore, one of the goals of this research was to develop a simpler and more dependable alternative. To this end, the use of a linear chain aldehyde (e.g. dedecanal) was investigated as a replacement for the linkers currently in use, like carbodiimide or glutaraldehyde.

## 2. Materials and methods

### 2.1. Materials

Acetone, petroleum ether, chloroform, methanol, diethylether, hydrochloric acid, acetic acid, sulfuric acid, ammonia, aluminum oxide, iodine, sodium chloride, potassium dihydrogen phosphate, sodium bisulfate, disodium hydrogen

phosphate, fuchsine, sodium tetraborate, sodium chromate, dedecanol, sucrose, silica gel G, and cholesterol, were all reagent grade from Merck, AG, (Darmstadt, Germany), and were used without further purification. Hydrated ferric chloride was from Hopkin & Williams, Ltd. (UK) and Analar Hipak and Ficol from Sigma, Inc. (St Louis, Missouri, USA). CD8, and antimouse IgG-FITC antibodies were gifts from the Blood Transfusion Organization (Tehran) and from the immunology laboratory at the College of Health Education, Tehran Medical Sciences University.

### 2.2. Instruments

Instruments used were a UV-visible spectrometer (model TCC-240A, Shimadzu, Japan), infrared spectrometer (model IR-4300, Shimadzu, Japan), particle size analyzer (gravito-centrifugal type-model SA-P3, Shimadzu, Japan), probe type ultrasonic generator (model MK2-3.75, MSE, France), variable autoinjector (model AG, Melsongen, Germany), rotary evaporator (model NAJ, EYELA, Japan), pH meter (model pH 196, WTW, Weilheim, Germany), fluorescent microscope (model Z3-UV 50 HP Zeiss, Germany), and a refrigerated ultracentrifuge (model 6-6, Imaco, Co, Iran) and ordinary equipment like oven, magnetic stirrer and blender.

### 2.3. Methods

#### 2.3.1. Colloidal magnetic particles

These were prepared by reacting a 25% ammonium hydroxide solution with ferro/ferric chloride according to standard procedures (Hamada and Matuevic, 1982) and were washed with phosphate buffered saline solution PBS (NaCl 137 mM; KCl 2.67 mM; Na<sub>2</sub>HPO<sub>4</sub> 6.4 mM; KH<sub>2</sub>PO<sub>4</sub> 1.4 mM, pH 7.2). Size distributions and their median were determined via the particle size analyzer as described below.

#### 2.3.2. Synthesis of dedecanal

This compound was prepared from the oxidation of dedecanol (Furniss et al., 1989) and the product was ascertained by the Schiff reagent (0.1 g fuchsine, 1.8 g NaHSO<sub>4</sub>, water 100 ml, 2 mM HCl) and IR spectroscopy.

### 2.3.3. Preparation of magnetic liposomes

Purified phosphatidylcholine (PC) was prepared from fresh egg yolk according to Singleton (Singleton and Gray, 1965), and its purity ascertained via thin layer chromatography on silica gel plates using a mixture of 65/5/1 vol/vol of chloroform/methanol/water as eluent. Two lipid compositions were used for the making of liposomes: (1) a mixture of 10/5 (w/w) of PC/cholesterol (blank); (2) a mixture of 10/5/1 (w/w/w) PC/dedecanal/cholesterol (for preparation of immunoliposomes) via a modification of reverse phase evaporation technique (Szoka and Papahadjopoulos, 1978). In this method 46 mg of the solid lipid mixture was dissolved in 4 ml of diethylether and 1 ml of PBS containing 0.01 g colloidal magnetic iron oxide added before sonication.

The resultant homogenate was placed in a rotary evaporator at 42°C and the organic solvent evaporated. Magnetic liposomes thus obtained were washed with borate buffer (6.84 g  $H_3BO_3$ , 9.53 g  $Na_2B_4O_7$ , 4.364 g NaCl in 1l water, pH 8.5), using a variable autoinjector connected to 0.2 ml bubble pipette whose bulb was placed in a strong hand held magnet (to retain the magnetic liposomes during continuous flow of the washing liquid; Fig. 1). Washing was continued until the emerging liquid was free of aldehyde (no color change against the Schiff indicator).

### 2.3.4. Determination of encapsulation efficiency

Non-magnetic or magnetic liposomes (lacking aldehyde) were separately prepared in sodium

chromate (0.1 M) and dialyzed against buffer to remove the unencapsulated sodium chromate. Subsequently, liposomes were lysed by treatment with Triton-X100. The concentration of the chromate ion encapsulated in the liposomal samples was determined by UV spectrophotometry at 380 nm (using a standard curve).

### 2.3.5. Size determination

Size and distribution, both of the colloidal magnetic particles as well as the magnetic liposomes, were determined via the particle size analyzer. Since such determinations require a prior knowledge of the particle densities and since the densities of liposomes were unknown and unavailable, their approximate values were determined using a sucrose density gradient column.

### 2.3.6. Antibody attachment

At first blank and aldehyde liposomes were incubated with the antibody (CD8, 5  $\mu$ g/mg lipid) at 4°C for 48 h and the antibodies were then conjugated with fluorescein isothiocyanate (FITC) at 4°C for 48 h. Unreacted antibodies and FITC were removed by chromatography on a G-25 Sephadex column (1  $\times$  15 cm). Magnetic liposomes were contacted with human anti-mouse IgG–FITC conjugate, (5  $\mu$ g/mg lipid, pH 8.5), and incubated at 4°C for 48 h. Unreacted antibodies were washed with the aid of a magnetic field in the same fashion as unreacted dedecanal described above. After thorough washing the fluorescent immuno- and immuno-magnetic lipo-




Fig. 1. The washing system.




Fig. 2. The liposomes conjugated with antibody and then FITC (fluorescence microscopy magnified  $40\times$ ).

somes were observed and photographed under a fluorescence microscope (Fig. 2).

#### 2.3.7. Attachment of lymphocytes to immunomagnetic liposomes

Lymphocytes were separated using a Ficoll solution (Duby et al., 1986) and subsequently attached to the CD8 antibody. The CD8 lymphocytes were mixed with the immunomagnetic liposomes prepared above and incubated at  $4^{\circ}\text{C}$  for 1 h. After separating the unattached liposomes (by centrifugation), the liposome-bonded cells were taken for fluorescence microscopy (Figs. 3 and 4).



Fig. 3. The magnetic liposomes conjugated with human-anti-mouse FITC antibody (fluorescence microscopy magnified  $450\times 1.25$ ).



Fig. 4. The immunomagnetic liposomes attached to lymphocyte cell (fluorescence microscopy magnified  $40\times$ ).

### 3. Results and discussion

Encapsulation efficiencies of ordinary and magnetic liposomes were found to be 29.5 and 19.6%, respectively, which clearly reflect the effect of magnetic particles present within the liposomes. The values are in satisfactory agreement with 20–60% reported by others (Szoka and Papahadjopoulos, 1978). The average size of the magnetic particles was  $\sim 0.3\ \mu\text{m}$  and that of the magnetic liposomes  $1.63\ \mu\text{m}$ . The latter is large compared to  $0.2\text{--}1\ \mu\text{m}$  usually reported for ordinary liposomes. This difference might be due to: (a) errors involved in the density values used; (b) formation of large unilamellar vesicles encapsulating the magnetic particles and their selective separation during the washing step in the magnetic field.

Blank liposomes (made of PC/cholesterol lacking dedecanal) did not bind the antibodies. Binding of the liposomes containing dedecanal in their bilayer clearly demonstrate that it offers a uniquely simple and easy procedure that is advantageous to the existing methods, like those based on glutaraldehyde, etc., because the binding sites are indigenously present on the liposome surfaces for direct attachment right after their formation, and toxicity of glutaraldehyde or carbodiimide and their associated multistep processes are avoided.

Availability of such easily prepared immunomagnetic liposomes is an aid in expanding the therapeutic application of liposomes. Their magnetic properties allow rapid and focussed delivery of drug-carrying immunoliposomes, before they are deleteriously affected by the blood system or otherwise. Besides, due to their unique specificity, use can be made of external vibrating magnetic fields in their deliberate, on site, rupture and immediate release of their contents.

#### 4. Conclusions

1. A simple and highly effective method was developed for preparing liposomes that readily bind protein molecules, like antibodies, to their exterior surfaces.
2. The extent of surface coverage can easily be controlled and varied by simply changing the amount of aldehyde initially used in the lipid mixture for preparing the liposomes.
3. Incorporation of colloidal magnetic particles yields liposomes that seem larger than ordinary liposomes.
4. Magnetic immunoliposomes prepared by this method exhibit satisfactory binding to cells carrying their corresponding antigenic determinants.
5. Immunomagnetic liposomes allow quick and focussed delivery of drugs to the sites of interest. Once localized these liposomes may readily and specifically bind to their target cells, where they could be ruptured by external stimuli to release their deadly potions.

#### Acknowledgements

The authors wish to express their sincere appreciation to Dr Shokri of College of Health Education, Dr Motee-yan and Mr Samiee of the Blood Transfusion Organization of Iran for their generous donation of antibodies and friendly cooperation and advice throughout the entire work. Special thanks goes to our colleagues Dr Behboodi of the Biology Department, Faculty of

Sciences; and Dr Gholiaee of the Institute of Biochemistry and Biophysics for their great efforts in helping us with fluorescence microscopy.

#### References

- Allen, T.M., Chonn, A., 1987. Large unilamellar liposomes with low uptake into the reticuloendothelial system. *FEBS Lett.* 223, 42–46.
- Allen, T.M., Hasen, C., Rutledge, J., 1989. Liposomes with prolonged circulation times, factors affecting uptake by reticuloendothelial and other tissue. *Biochem. Biophys. Acta* 981, 27–35.
- Allen, T.M., 1990. Membrane contact, Fusion, Hexagonal transition in phosphatidylethanolamine liposomes. *Biochemistry* 29, 2976–2985.
- Allen, T.M., Brandies, E., Hansen, C.B., Kao, G.Y., Zalipsky, S., 1995. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. *Biochem. Biophys. Acta* 1237, 99–108.
- Aslam, M., Dent, A., 1998. *Bioconjugation*. Macmillan Reference Ltd, London, pp. 370–422.
- Bangham, A.D., Horn, R.W., 1964. Negative staining of phospholipids and their structural modification by surface active agents as observed by electron microscopy. *J. Mol. Biol.* 8, 660–668.
- Connor, J., Huang, L., 1986. pH-sensitive immunoliposomes as an efficient and target specific carrier for antitumor drugs. *Cancer Res.* 46, 3431–3435.
- De Cuypur, M., Joniau, M., 1988. Magnetoliposomes. *Eur. Biophys. J.* 15, 311–319.
- Duby, D.P., Yunis, I., Yunis, E.J., 1986. Cellular Typing: Mixed Lymphocyte Response and Cell-Mediated Lympholysis Chap. 131. In: Rose, N.R., Friedman, H., Fahey, J.L. (Eds.), *Manual of Clinical Laboratory Immunology*. 3d Ed.; Am. Soc. Microbiol., Wash. D.C.; pp. 847–858.
- Furniss, B.S. Hannaford, A.J., Smith, P.W.G., Tatchel, A.R., 1989. *Vogel's Textbook of Practical Organic Chemistry* 5th Ed.; Longman Scientific and Technical, Essex, p. 588.
- Furukawa, K., Sahasrabudde, C.G., 1990. A novel method of human B cell activation by liposomes coated with F (ab) fragment of anti-g M. *J. Immunol. Meth.* 131, 105–112.
- Gabizon, A., Papahadjopoulos, D., 1988. Liposome formulation with prolonged circulation time in blood and enhanced uptake by tumor. *Pro. Natl. Acad. Sci.* 85, 6949–6954.
- Gabizon, A., 1992. The role of surface charge and hydrophobic groups on liposomes clearance in vivo. *Biochem. Biophys. Acta* 1183 (1), 94–100.
- Gray, A., Morgan, J., 1991. Liposomes in haematology. *Blood Rev.* 5, 258–272.
- Gregoriadis, G., Ryman, B.E., 1972. Fate of protein containing liposomes injected into rats: an approach to treatment of storage diseases. *Eu. J. Biochem* 24, 485–491.

- Gregoriadis, G., Florence, A.T., (1992); Efficient Entrapment of Solutes in Microfluidized Small Dehydration-Rehydration Liposomes, Chapt. 2 in: *Liposome Technology*, Vol.1 ed. G. Gragoriadis, 2nd Ed.; CRC Press Boca Raton FL; pp. 37–49.
- Gregoriadis, G., Allison, A.C., 1980. *Liposomes in Biological Systems*. Wiley Interscience, New York.
- Hamada, S., Matuevic, E., 1982. Formation of monodispersed colloidal cubic haematite particles in ethanol + water solution. *J. Faraday Trans.* 78, 2147–2156.
- Hansen, C.B., Kao, G.Y., Moase, E.H., Zalipsky, S., Allen, T.M., 1995. Attachment of antibodies to sterically stabilized liposomes: evolution comparison and optimization of coupling procedures. *Biochem. Biophys. Acta* 1239, 133–144.
- Holmberg, E.G., Reuer, Q.R., 1994. Delivery of plasmid DNA to glial cells using pH-sensitive immunoliposomes. *Biochem. Biophys. Res. Commun.* 201 (2), 888–893.
- Huang, L., Kennel, S.J., 1979. Binding immunoglobulin G to phosphotidyl choline vesicles by sonication. *Biochemistry* 18, 1702–1707.
- Huang, A., Huang, L., Kennel, S., 1980. Covalently coupled with a fatty acid. *J. Biol. Chem.* 255, 8015–8018.
- Jones, M.N., Chappman, D., 1995. *Micelles, Monolayers and Biomembranes*. John Wiley, New York, pp. 117–143.
- Kato, Y., Kiwada, H., 1986. Feasibility of magnetic liposomes as a targeting device for drugs. *Chem. Pharm. Bull.* 34 (10), 4253–4258.
- Klibanov, A.L., Maruyama, K., Huang, L., 1991. Influence of surface hydrophobicity of liposomes on their interaction with plasma protein and clearance from the circulation: studied with poly(ethylene glycol) coated vesicle. *Biochem. Biophys. Acta* 1062 (1), 77–82.
- Knight, C.G., 1981. *Liposomes: from Physical Structure to Therapeutic Application*. Elsevier, Amsterdam.
- Lopez-Berestein, G., Fidler, I.J., 1989. *Liposomes in Therapy of Infectious Diseases and Cancer*. Allan, R. Liss, New York.
- Magee, W.E., Miller, G., 1979. Liposomes containing antiviral antibody can protect from virus infection. *Nature* 235, 339–341.
- Margolis, L.B., Namit, V.A., 1983. Magnetoliposomes: another principle of cell sorting. *Biochem. Biophys. Acta* 735, 193–195.
- Ostro, M.J., 1987. *Liposomes: From Biophysical to Therapeutics*. Marcel Dekker, New York.
- Patel, K., Baldeschwieller, J.D., 1983. Suppression of liver uptake of liposomes by dextran sulfate 500. *Pro. Natl. Acad. Sci.* 80, 6518–6522.
- Peeters, P.A.M., Strom, G., Crommelin, D.J.A., 1987. Immunoliposomes in vivo state of the art. *Adv. Drug Deliv. Rev.* 1, 249–266.
- Pidgeon, C., Hunt, C.A., 1987. Photolabile liposomes and carriers. *Methods in Enzymology* 149, 99–111.
- Proffit, W.R., 1986. Liposomal blockade of reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. *Sci.* 220, 502–508.
- Scheffold, A., Milteni, S., 1995. Magnetofluorescent liposomes for increased sensitivity of immunofluorescence. *Immunotechnology* 1 (2), 127–137.
- Schwendener, R.A., Schott, H, Barth, R.F., 1990. Comparative studies of preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome target cell binding by cytofluorometry and electron microscopy. *Biochem. Biophys. Acta* 1026, 69–79.
- Singleton, W.S., Gray, M.S., 1965. Chromatographically homogeneous lecithin from egg phospholipid. *J. Am. Chem. Sci.* 42, 53–56.
- Sollivan, S.M., Huang, L, 1986. Enhanced delivery to target cells by heat sensitive immunoliposomes. *Pro. Natl. Acad. Sci.* 83 (16), 6117–6121.
- Stonsons, V, Mallett, P., 1981. Targeted liposomes: a method for preparation and analysis. *Anal. Biochem.* 111, 54–59.
- Szoka, F, Papahadjopoulos, D., 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation. *Pro. Natl. Acad. Sci.* 75 (9), 4194–4198.
- Torchilin, V.P., Khaw, B.A., 1979. Preservation of antimyosin activity after covalent coupling to liposomes. *Biochem. Biophys. Res. Commun.* 89, 1114–1119.
- Viroonchatapan, E., Sato, H., 1996. Magnetic targeting of thermosensitive magnetoliposomes to mouse liver in an insituation on-line perfusion system. *Life Sci.* 58 (24), 2251–2261.
- Wang, C.Y., Huang, L., 1989. High efficient DNA delivery mediated by pH-sensitive immunoliposomes. *Biochemistry* 28, 9508–9514.
- Wessing, V., Lasch, J., 1986. A new hydrophobic anchor for the attachment of proteins to liposomes membranes. *FEBS Lett.* 202 (1), 86–90.
- Woodle, M.C., Lasic, D., 1992. Sterically stabilized. *Biochem. Biophys. Acta* 1113, 171–199.
- Yatvin, M.B., Krutz, W., 1980. pH-sensitive liposomes: possible clinical implications. *Sci* 210, 1253–1256.
- Yatvin, M.B., Weinstein, J.N., 1990. Design of liposomes for enhanced local released of drugs by hyperthermia. *Sci.* 202, 1290–1295.